[1][2][3][4][5] Conversely, 3-F-BPAP does not antagonize the catecholaminergic activity enhancer (CAE) effects of the phenethylamine-derived selegiline (L-deprenyl) and phenylpropylaminopentane (PPAP).

[1][2][3][4] This suggests that different MAEs like BPAP and selegiline may not be identical in their actions and might be acting via different receptor subtypes.

[1][2][3][4][6][5] In contrast to 3-F-BPAP however, the TAAR1 antagonist EPPTB antagonizes the MAE effects of both BPAP and selegiline.

[7][8] 3-F-BPAP has a weak MAE effect itself but with much lower potency than BPAP.

[2][3][4][5] The effects of MAEs like BPAP and selegiline appear to be mediated by TAAR1 agonism, and hence 3-F-BPAP may be acting as a TAAR1 antagonist (or weak partial agonist).